NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Holdings Trimmed by Readystate Asset Management LP

Readystate Asset Management LP trimmed its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 11.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 229,662 shares of the company's stock after selling 30,738 shares during the quarter. Readystate Asset Management LP owned about 0.21% of NewAmsterdam Pharma worth $4,701,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $50,000. National Bank of Canada FI purchased a new position in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of NewAmsterdam Pharma by 19.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after buying an additional 596 shares in the last quarter. Avanza Fonder AB purchased a new position in shares of NewAmsterdam Pharma during the 1st quarter worth approximately $127,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $154,000. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma stock traded up $0.06 during midday trading on Friday, reaching $23.45. The stock had a trading volume of 424,083 shares, compared to its average volume of 882,748. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $27.29. The stock has a market capitalization of $2.63 billion, a PE ratio of -12.46 and a beta of -0.03. The stock's 50-day simple moving average is $19.70 and its 200 day simple moving average is $20.15.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The company had revenue of $2.98 million for the quarter, compared to analyst estimates of $1.46 million. NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. Equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Cantor Fitzgerald started coverage on NewAmsterdam Pharma in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price objective for the company. Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. The Goldman Sachs Group started coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a "neutral" rating and a $27.00 price target for the company. Finally, Stifel Nicolaus started coverage on NewAmsterdam Pharma in a research report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target for the company. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $41.30.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper bought 2,520 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were acquired at an average cost of $18.43 per share, with a total value of $46,443.60. Following the completion of the transaction, the director owned 3,024,873 shares in the company, valued at $55,748,409.39. The trade was a 0.08% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Douglas F. Kling sold 51,043 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $21.10, for a total value of $1,077,007.30. Following the sale, the chief operating officer directly owned 44,000 shares in the company, valued at approximately $928,400. The trade was a 53.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have bought 12,364 shares of company stock worth $236,839 and have sold 198,612 shares worth $4,025,887. 20.84% of the stock is currently owned by insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.